BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5^th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA.

Details are as follows:

5^th Annual ALS Drug Development Summit

Oral Presentation Title: Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive Methodologies

Session Title: Redefining Biomarkers and Trial Design to Accelerate Neurodegenerative Disease Therapies

Presenter: Javier San Martin, M.D., Chief Medical Officer, LeonaBio

Presentation Date and Time: Wednesday, June 3, 2026, at 2:50 p.m. ET

Location: The Colonnade Hotel, Boston, MA

BIO International Convention

Panel Presentation Title: The Future of Oncology Trials: Aligning Science, Regulation, and Investment in Overall Survival

Presenter: David Portman, M.D., Chief Executive Officer, Sermonix; Oncology Consultant, LeonaBio

Panel Date and Time: Wednesday, June 24, 2026, at 11:00 a.m. PT

Location: Room 32AB, San Diego Convention Center, San Diego, CA

About LeonaBio

LeonaBio, headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients' lives. Our lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. With a strong commitment to scientific excellence and patient-centered innovation, we are dedicated to developing meaningful new therapies for those who need them most.

For more information, visit www.leonabio.com.

Investor & Media Contact:

Julie Rathbun

LeonaBio

Julie.rathburn@leonabio.com

206-769-9219

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June